Ate van der Gaast

Ate van der Gaast at Erasmus MC led the CROSS trial, establishing preoperative carboplatin/paclitaxel with concurrent radiotherapy (the CROSS regimen) as the standard neoadjuvant treatment for resectable esophageal cancer. This landmark trial demonstrated significant improvements in pathologic complete response rates and overall survival. His work has been adopted globally as the primary standard of care for locally advanced resectable esophageal cancer.